These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 26608985)
21. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517 [TBL] [Abstract][Full Text] [Related]
22. Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia. Giordano P; Lenato GM; Pierucci P; Suppressa P; Altomare M; Del Vecchio G; Di Bitonto G; De Mattia D; Guanti G; Sabbà C J Pediatr Hematol Oncol; 2009 Aug; 31(8):577-82. PubMed ID: 19636272 [TBL] [Abstract][Full Text] [Related]
23. Reduced endothelial secretion and plasma levels of transforming growth factor-beta1 in patients with hereditary hemorrhagic telangiectasia type 1. Letarte M; McDonald ML; Li C; Kathirkamathamby K; Vera S; Pece-Barbara N; Kumar S Cardiovasc Res; 2005 Oct; 68(1):155-64. PubMed ID: 15907823 [TBL] [Abstract][Full Text] [Related]
24. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Kanellopoulou T; Alexopoulou A Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519 [TBL] [Abstract][Full Text] [Related]
26. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. Dupuis-Girod S; Bailly S; Plauchu H J Thromb Haemost; 2010 Jul; 8(7):1447-56. PubMed ID: 20345718 [TBL] [Abstract][Full Text] [Related]
27. Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study. Kroon S; Snijder RJ; Hosman AE; Vorselaars VMM; Disch FJM; Post MC; Mager JJ Angiogenesis; 2021 May; 24(2):379-386. PubMed ID: 33211216 [TBL] [Abstract][Full Text] [Related]
28. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. Kim YH; Kim MJ; Choe SW; Sprecher D; Lee YJ; P Oh S J Thromb Haemost; 2017 Jun; 15(6):1095-1102. PubMed ID: 28339142 [TBL] [Abstract][Full Text] [Related]
29. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. Ardelean DS; Jerkic M; Yin M; Peter M; Ngan B; Kerbel RS; Foster FS; Letarte M Angiogenesis; 2014 Jan; 17(1):129-46. PubMed ID: 24061911 [TBL] [Abstract][Full Text] [Related]
30. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Fleagle JM; Bobba RK; Kardinal CG; Freter CE Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516 [TBL] [Abstract][Full Text] [Related]
31. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report. Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613 [TBL] [Abstract][Full Text] [Related]
34. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Merlo CA; Yin LX; Hoag JB; Mitchell SE; Reh DD Int Forum Allergy Rhinol; 2014 Nov; 4(11):921-5. PubMed ID: 25145809 [TBL] [Abstract][Full Text] [Related]